JP2023534812A5 - - Google Patents
Info
- Publication number
- JP2023534812A5 JP2023534812A5 JP2023503110A JP2023503110A JP2023534812A5 JP 2023534812 A5 JP2023534812 A5 JP 2023534812A5 JP 2023503110 A JP2023503110 A JP 2023503110A JP 2023503110 A JP2023503110 A JP 2023503110A JP 2023534812 A5 JP2023534812 A5 JP 2023534812A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- items
- dendrimer
- composition according
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063053228P | 2020-07-17 | 2020-07-17 | |
| US63/053,228 | 2020-07-17 | ||
| PCT/US2021/042097 WO2022016120A1 (en) | 2020-07-17 | 2021-07-16 | Dendrimer compositions and methods for drug delivery to injured kidney |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023534812A JP2023534812A (ja) | 2023-08-14 |
| JP2023534812A5 true JP2023534812A5 (enExample) | 2024-07-24 |
Family
ID=79555049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023503110A Pending JP2023534812A (ja) | 2020-07-17 | 2021-07-16 | 損傷した腎臓に薬物送達するためのデンドリマー組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230364244A1 (enExample) |
| EP (1) | EP4181913A4 (enExample) |
| JP (1) | JP2023534812A (enExample) |
| CN (1) | CN116249558A (enExample) |
| AU (1) | AU2021310470A1 (enExample) |
| CA (1) | CA3189682A1 (enExample) |
| IL (1) | IL299891A (enExample) |
| PH (1) | PH12023550133A1 (enExample) |
| WO (1) | WO2022016120A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022552818A1 (en) | 2020-04-24 | 2024-03-25 | Ashvattha Therapeutics Inc | Dendrimer compositions and methods for treatment of severe acute respiratory distress syndrome |
| EP4237009A4 (en) * | 2020-10-30 | 2025-09-24 | Ashvattha Therapeutics Inc | Radiolabeled ether dendrimer conjugates for PET imaging and radiotherapy |
| US20250333732A1 (en) * | 2022-05-23 | 2025-10-30 | Empirico Inc. | Treatment of sos2 related diseases and disorders |
| WO2025137151A2 (en) * | 2023-12-18 | 2025-06-26 | The Johns Hopkins University | Dendrimer compositions for the treatment of atherosclerosis, obesity, and metabolic syndromes |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012116753A (ja) * | 2009-03-26 | 2012-06-21 | Nippon Chemiphar Co Ltd | ペルオキシソーム増殖剤活性化受容体の活性化剤 |
| WO2011053618A2 (en) * | 2009-10-30 | 2011-05-05 | The Regents Of The University Of Michigan | Hydroxyl-terminated dendrimers |
| WO2016025741A1 (en) * | 2014-08-13 | 2016-02-18 | The Johns Hopkins University | Selective dendrimer delivery to brain tumors |
| CN105879055A (zh) * | 2014-11-11 | 2016-08-24 | 董勤 | 载cxcr4小分子rna聚酰胺树枝状聚合物纳米微粒 |
| JP7108306B2 (ja) * | 2015-10-29 | 2022-07-28 | ザ・ジョンズ・ホプキンス・ユニバーシティー | デンドリマー組成物ならびに壊死性腸炎および他の胃腸障害の処置における使用 |
| JP7088473B2 (ja) * | 2015-10-29 | 2022-06-21 | ザ・ジョンズ・ホプキンス・ユニバーシティー | ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法 |
| US11771702B2 (en) * | 2018-11-30 | 2023-10-03 | Amiram Goldblum | Agonists of PPAR-δ |
| AU2020397063A1 (en) * | 2019-12-04 | 2022-07-07 | Ashvattha Therapeutics, Inc. | Dendrimer compositions and methods for drug delivery |
| AU2020397064A1 (en) * | 2019-12-04 | 2022-07-07 | Ashvattha Therapeutics, Inc. | Triantennary N-Acetylgalactosamine modified hydroxyl polyamidoamine dendrimers and methods of use thereof |
-
2021
- 2021-07-16 EP EP21841182.5A patent/EP4181913A4/en active Pending
- 2021-07-16 CN CN202180062066.1A patent/CN116249558A/zh active Pending
- 2021-07-16 IL IL299891A patent/IL299891A/en unknown
- 2021-07-16 CA CA3189682A patent/CA3189682A1/en active Pending
- 2021-07-16 US US18/016,262 patent/US20230364244A1/en active Pending
- 2021-07-16 PH PH1/2023/550133A patent/PH12023550133A1/en unknown
- 2021-07-16 WO PCT/US2021/042097 patent/WO2022016120A1/en not_active Ceased
- 2021-07-16 AU AU2021310470A patent/AU2021310470A1/en active Pending
- 2021-07-16 JP JP2023503110A patent/JP2023534812A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Maeda et al. | Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS | |
| JP6738376B2 (ja) | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 | |
| JP7298818B2 (ja) | 低ナトリウムポロキサマー１８８製剤および使用方法 | |
| CN115135304A (zh) | Glp-1组合物及其用途 | |
| CN102088997A (zh) | 用于治疗糖尿病和其他慢性疾病的组合物 | |
| CN104159614A (zh) | TNF-α抗体的药物制剂 | |
| WO2021152184A1 (en) | Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist | |
| WO2015090162A1 (zh) | 一种含有阿达木单抗的药物组合物 | |
| AU2017203290B2 (en) | Multidrug infusion for pain control | |
| TW202500183A (zh) | 包括環糊精的醫藥調配物 | |
| JP2023553538A (ja) | 抗ｃｓｆ１および抗ｃｓｆ１ｒ抗体の高濃度製剤 | |
| JP2009504650A5 (enExample) | ||
| Kaminskas et al. | A 30 kDa polyethylene glycol-enfuvirtide complex enhances the exposure of enfuvirtide in lymphatic viral reservoirs in rats | |
| EP4631522A1 (en) | Il-17a antibody formulation and use thereof | |
| KR20220064998A (ko) | 콜레스테롤 관련 질환을 예방하거나 치료하기 위한 방법에 있어서 항 pcsk9 항체의 용도 | |
| CN117379529A (zh) | 用于增强阳离子大环肽的全身递送能力、耐受性和效力的组合物和方法 | |
| CN117531007A (zh) | 一种长效glp-1药物制剂及其用途 | |
| CN116635023A (zh) | 用于治疗糖尿病的离子液体制剂 | |
| CN112451654A (zh) | 司来普伐肽的新用途 | |
| KR100679925B1 (ko) | 신규한 ５―플루오로우라실 좌제 조성물 | |
| WO2001026677A1 (fr) | Complexe a base d'interferon et son utilisation en medecine | |
| CN120187408A (zh) | 包含苯磺酰胺噻唑化合物的组合物 | |
| CN116390715A (zh) | 康赛珠单抗的药物制剂及其制备方法 | |
| TW202421653A (zh) | 用TACI-Fc融合蛋白治療膜性腎病的方法 | |
| CN117298247A (zh) | Mdp类似物在制备用于治疗炎症性肠病的药物中的用途 |